Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Food safety diagnostics might feel far from Wall Street, yet Neogen’s supply-chain complexity shows up in hundreds of pages of disclosures. Tracking which genomic test kit drives revenue, or when management sells shares, is difficult. That’s why investors hunting for “Neogen insider trading Form 4 transactions” or the latest “Neogen quarterly earnings report 10-Q filing” often lose hours scrolling through EDGAR.
Stock Titan fixes this. Our AI reads every 10-K, 10-Q, 8-K and proxy the moment it is released, pushes “Neogen Form 4 insider transactions real-time” to your dashboard, and offers “Neogen SEC filings explained simply” with crisp language and data visualizations. Within seconds you’ll see a “Neogen earnings report filing analysis,” flagging segment sales for food safety, animal safety and genomics, plus cash flow shifts tied to acquisitions. Interactive links jump you straight to risk factors, while sidebars answer “understanding Neogen SEC documents with AI” without legalese.
Want specifics? The “Neogen annual report 10-K simplified” highlights R&D spend on LAMP molecular assays and global compliance costs. The “Neogen proxy statement executive compensation” module benchmarks pay packages against peer diagnostics firms. Alerts on “Neogen executive stock transactions Form 4” reveal buying patterns before material announcements, and our dashboard keeps the “Neogen 8-K material events explained” in plain sight when recalls or mergers hit. Whether you compare quarter-over-quarter allergen test kit sales, monitor insider sentiment, or review governance votes, Stock Titan delivers the intelligence you need, updated in real time and ready for decision making.
NEOGEN (NEOG) reported a routine insider equity event. A director acquired 1,777 shares of common stock on 10/27/2025 through the vesting and settlement of restricted stock units, reflected with transaction code M. The filing lists a price of $6.19 associated with the conversion. Following this transaction, the director beneficially owns 43,347 shares, held directly.
Neogen Corp (NEOG) disclosed a director transaction on a Form 4. On October 27, 2025, 1,777 restricted stock units vested and were settled for an equal number of common shares at a labeled price of $6.19 per share (Transaction Code M).
After the settlement, the director beneficially owned 19,117 shares, held directly. The filing notes that each RSU was the economic equivalent of one share of common stock, and these RSUs vested and were settled for the same number of shares on the stated date.
Neogen Corp (NEOG) insider activity: The company’s Chief Legal Officer reported the vesting and settlement of 9,474 restricted stock units into common stock on 10/27/2025, shown with transaction code M at a stated price of $6.19. A follow-on entry with code F reflects the disposition of 2,085 shares, typically for tax withholding, also at $6.19. After these transactions, the officer directly owned 57,240 shares.
The remarks clarify that each RSU equals one share of common stock and that the RSUs vested on October 27, 2025.
NEOGEN (NEOG) reported an insider transaction by its Chief Financial Officer. On October 27, 2025, 15,504 restricted stock units vested and were settled into the same number of common shares (code M) at $6.19. To cover taxes, 4,261 shares were withheld (code F) at $6.19. After these transactions, the officer directly owned 81,024 shares. Each RSU is equivalent to one share of common stock.
Neogen (NEOG) reported an insider equity event. On October 27, 2025, a former COO had 15,504 restricted stock units vest and convert to common stock (code M at
Each RSU was the economic equivalent of one share of common stock.
Neogen Corp (NEOG) insider filing: An officer (Former CEO) reported RSU vesting and related share movements. On October 27, 2025, 38,759 restricted stock units vested and were settled into an equal number of common shares at $6.19 per share (code M). A separate transaction disposed of 8,527 shares at $6.19 (code F).
Following these transactions, the reporting person beneficially owned 363,081 shares, held directly.
Neogen Corp (NEOG) director reported an RSU vesting on October 27, 2025: 3,553 shares of common stock were acquired via a code “M” conversion at $6.07 per share. Following the settlement, the reporting person beneficially owns 47,913 shares, held directly.
Each RSU equaled one share, and the RSUs vested and were settled for an equal number of shares on October 27, 2025.
Neogen Corp (NEOG) reported a routine insider equity event. A director converted restricted stock units into common shares on 10/27/2025 (Transaction Code M). 2,025 shares of common stock were acquired at $6.19 per share upon RSU vesting and settlement. Following the transaction, the director beneficially owns 30,725 shares directly. The filing also lists 4,050 derivative securities (RSUs) beneficially owned after the reported transaction.
Neogen Corp (NEOG) reported an insider equity change by a director. On October 27, 2025, 2,025 restricted stock units vested and were settled into 2,025 shares of common stock (transaction code M) at a listed price of $6.19 per share. Following this settlement, the reporting person directly owned 94,570 shares.
FAQ
What is the current stock price of Neogen (NEOG)?
What is the market cap of Neogen (NEOG)?
